trial · primary record
Talquetamab
Relapsed/ Refractory Multiple Myeloma
| Phase | Phase 1 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 74 |
| Primary completion | 2027-12-31 |
| Primary endpoint | Number of Participants with Adverse Events (AEs) |
| Registry ID | NCT05338775 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:44.069Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT05338775
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Talquetamab · compound